ICON Expands Asia Pacific Footprint With New Focus On Southeast Asian Countries
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Driven by increasing interest for drug development programs in Southeast Asia, Ireland-based ICON is expanding its Asia Pacific footprint in the Philippines
You may also be interested in...
Boehringer Ingelheim And Ecron Acunova Think Regionally For Clinical Trials – Bangalore Bio
Boehringer sees advantages to a long-term, and expansive CRO partnership instead of carving up markets in Asia.
ICON Goes Local As China CRO Market Heats Up
Acquisition of BeijingWits will boost ICON’s clinical trial capabilities in China and the Asia Pacific region.
ICON Opens New Asian Offices To Keep Pace With Growing Demand For More Trials In Emerging Markets
BEIJING - Ireland-headquartered global contract research organization ICON is expanding its presence in the Asia Pacific region due to the growing attractiveness of conducting clinical trials in the region